Antitumor activity of the dual PI3K/mTOR inhibitor gedatolisib and the involvement of ABCB1 in gedatolisib resistance in canine tumor cells.
ATP Binding Cassette Transporter, Subfamily B, Member 1
/ metabolism
Animals
Dogs
Drug Resistance, Neoplasm
/ drug effects
Morpholines
/ pharmacology
Neoplasms
/ drug therapy
Phosphatidylinositol 3-Kinases
/ metabolism
Protein Kinase Inhibitors
/ pharmacology
TOR Serine-Threonine Kinases
/ metabolism
Triazines
/ pharmacology
ABCB1
PI3K
canine tumors
gedatolisib
mTOR
Journal
Oncology reports
ISSN: 1791-2431
Titre abrégé: Oncol Rep
Pays: Greece
ID NLM: 9422756
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
01
11
2019
accepted:
25
02
2021
entrez:
28
1
2022
pubmed:
29
1
2022
medline:
4
2
2022
Statut:
ppublish
Résumé
The phosphatidylinositol 3‑kinase/mammalian target of rapamycin (PI3K/mTOR) signaling pathway is a therapeutic target for various types of human tumors, and dual PI3K/mTOR inhibitors demonstrate antitumor activities in both preclinical and clinical studies. However, resistance mechanisms limit their abilities. As the molecular mechanisms involved in the cellular resistance are not clear in any canine tumors, an understanding of resistance mechanisms would support the potential use of dual PI3K/mTOR inhibitors in canine tumors. The antitumor activity of gedatolisib on cell viability, protein phosphorylation, and cell cycle distribution was assessed using 12 canine tumor cell lines from 6 types of tumors. In addition, the molecular determinants involved in the cellular sensitivity to gedatolisib were explored by investigating the involvement of serum‑and‑glucocorticoid‑induced kinase 1 (SGK1),
Identifiants
pubmed: 35088890
doi: 10.3892/or.2022.8272
pii: 61
pmc: PMC8848474
doi:
pii:
Substances chimiques
ATP Binding Cassette Transporter, Subfamily B, Member 1
0
Morpholines
0
Protein Kinase Inhibitors
0
Triazines
0
gedatolisib
96265TNH2R
TOR Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Sci Rep. 2018 Jan 26;8(1):1652
pubmed: 29374181
Vaccine. 2009 Oct 9;27(43):5989-97
pubmed: 19665610
Mol Pharmacol. 1994 Oct;46(4):627-38
pubmed: 7969041
Drug Resist Updat. 2015 Jan;18:1-17
pubmed: 25554624
Nat Rev Drug Discov. 2014 Feb;13(2):140-56
pubmed: 24481312
J Vet Med Sci. 2001 Sep;63(9):1031-4
pubmed: 11642274
Vet J. 2015 Apr;204(1):60-5
pubmed: 25773167
Trends Biochem Sci. 2011 Jun;36(6):320-8
pubmed: 21531565
Biochem J. 2013 Jun 15;452(3):499-508
pubmed: 23581296
J Comp Pathol. 2012 Aug-Oct;147(2-3):171-6
pubmed: 22289273
Clin Cancer Res. 2010 Nov 15;16(22):5424-35
pubmed: 20884625
Mol Cancer Ther. 2015 May;14(5):1224-35
pubmed: 25724664
BMC Vet Res. 2012 Jul 29;8:128
pubmed: 22839755
Nat Rev Cancer. 2015 Jan;15(1):7-24
pubmed: 25533673
Cancer Cell. 2016 Aug 8;30(2):229-242
pubmed: 27451907
Vet Pathol. 2011 Sep;48(5):1029-34
pubmed: 21245282
Drug Metab Dispos. 2009 Feb;37(2):359-65
pubmed: 18971320
Vet Comp Oncol. 2015 Sep;13(3):288-304
pubmed: 23745794
Int J Cancer. 2014 Jul 15;135(2):253-63
pubmed: 24122334
PLoS One. 2010 Jun 08;5(6):e11013
pubmed: 20543980
Am J Vet Res. 2009 Feb;70(2):263-9
pubmed: 19231960
J Vet Med Sci. 2006 Dec;68(12):1343-6
pubmed: 17213706
J Clin Oncol. 2010 Feb 20;28(6):1075-83
pubmed: 20085938
Cancer Lett. 2016 Jan 1;370(1):153-64
pubmed: 26499806
J Vet Med Sci. 2005 Apr;67(4):385-91
pubmed: 15876788
Clin Cancer Res. 2003 Jul;9(7):2755-68
pubmed: 12855656
Clin Cancer Res. 2011 Apr 15;17(8):2373-84
pubmed: 21372221
J Clin Invest. 2011 Apr;121(4):1231-41
pubmed: 21490404
J Vet Med Sci. 2002 Feb;64(2):169-72
pubmed: 11913557
J Vet Med Sci. 1999 Apr;61(4):361-7
pubmed: 10342286
Clin Cancer Res. 2011 May 15;17(10):3193-203
pubmed: 21325073
Am J Vet Res. 2008 Aug;69(8):1079-84
pubmed: 18672974
Oncogene. 2011 Jun 2;30(22):2547-57
pubmed: 21278786
J Vet Med Sci. 2004 Nov;66(11):1437-40
pubmed: 15585963
J Vet Med Sci. 1994 Dec;56(6):1167-9
pubmed: 7696411
Expert Rev Anticancer Ther. 2007 Apr;7(4):447-59
pubmed: 17428165
Insect Biochem Mol Biol. 2015 May;60:59-67
pubmed: 25796479
Nat Rev Clin Oncol. 2018 May;15(5):273-291
pubmed: 29508857
Pigment Cell Melanoma Res. 2016 Nov;29(6):643-655
pubmed: 27463366
Cell Physiol Biochem. 2016;39(5):1863-1876
pubmed: 27771704
EMBO J. 1999 Jun 1;18(11):3024-33
pubmed: 10357815
Front Oncol. 2012 Aug 31;2:109
pubmed: 22970424
In Vitro Cell Dev Biol. 1988 Mar;24(3):223-9
pubmed: 3350786
Cancer Cell. 2012 Dec 11;22(6):796-811
pubmed: 23238015
J Comp Pathol. 2015 Feb-Apr;152(2-3):138-44
pubmed: 25670666
Gynecol Oncol. 2016 Jul;142(1):62-69
pubmed: 27103175
PLoS One. 2018 Jul 16;13(7):e0200634
pubmed: 30011343
Biochem J. 2008 Dec 15;416(3):375-85
pubmed: 18925875
J Gen Virol. 2012 Mar;93(Pt 3):668-680
pubmed: 22090211
Vet Clin North Am Small Anim Pract. 2014 Sep;44(5):893-908
pubmed: 25174906
Nucleic Acids Res. 1994 Nov 11;22(22):4673-80
pubmed: 7984417
BMC Vet Res. 2012 May 30;8:73
pubmed: 22647622